Literature DB >> 6277381

Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin.

B Eriksson, B Oberg, B Wahren.   

Abstract

Several pyrophosphate analogues have been compared for their ability to inhibit the activities of isolated cytomegalovirus (CMV) DNA polymerase, herpes simplex virus type 1 (HSV 1) DNA polymerase and calf thymus DNA polymerase alpha. The most effective inhibitors were phosphonoformate and phosphonoacetate. Although not identical, the structural requirements for compounds inhibitory to CMV and HSV-1 DNA polymerase were specific, with two negatively charged groups in close vicinity. The CMV DNA polymerase was more susceptible to certain phosphonoacetates containing bulky hydrophobic alpha-substituents than was the HSV-1 DNA polymerase. No example of the converse preference was found. The inhibition of CMV DNA polymerase by phosphonoformate, hypophosphate, alpha-hydroxyphosphonoacetate and alpha-nonylphosphonoacetate was linear non-competitive with the deoxyribonucleoside triphosphates as variable substrates. Phosphonoformate, phosphonoacetate, and to a lesser extent alpha-hydroxyphosphonoacetate, carbonyldiphosphonate and alpha-nonylphosphonoacetate also inhibited the focus formation by CMV in cell-culture.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277381     DOI: 10.1016/0167-4781(82)90018-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

3.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

4.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Temporal dynamics of cytomegalovirus chromatin assembly in productively infected human cells.

Authors:  Alexandra Nitzsche; Christina Paulus; Michael Nevels
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

6.  Activity of the cytomegalovirus genome in the presence of PPi analogs.

Authors:  B Wahren; U Rudén; H Gadler; B Oberg; B Eriksson
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

7.  In vitro recovery of resistant retrovirus isolates after exposure to phosphonoformate.

Authors:  O Muratore; O E Varnier; S P Raffanti; G C Schito
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

8.  Early interactions between human cytomegalovirus and cells.

Authors:  B Wahren; L Einhorn; H Gadler
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

9.  Acyclic guanosine analogs as inhibitors of human cytomegalovirus.

Authors:  B Wahren; A Larsson; U Rudén; A Sundqvist; E Sølver
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

10.  Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Authors:  Kalyan Das; Jan Balzarini; Matthew T Miller; Anita R Maguire; Jeffrey J DeStefano; Eddy Arnold
Journal:  ACS Chem Biol       Date:  2016-06-06       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.